



NEWS RELEASE
FOR IMMEDIATE RELEASE

TSX: AMF

**AMORFIX AND BIOMOSAICS COLLABORATE TO DEVELOP A BLOOD TEST
FOR LIVER CANCER SUPPORTED BY GRANT FROM THE
ONTARIO INSTITUTE FOR CANCER RESEARCH**

TORONTO, Ontario and BURLINGTON, Vermont – April 23, 2009 – Amorfix Life Sciences Ltd. and BioMosaics Inc. today announced a collaboration to develop and commercialize a blood-based assay for early detection of hepatocellular carcinoma (HCC) or primary liver cancer. This effort is possible due to an "Intellectual Property Development and Commercialization Program" investment of \$280,000 from the Ontario Institute for Cancer Research (OICR) to Sunnybrook Research Institute (SRI) at Sunnybrook Health Sciences Centre (Sunnybrook). The collaboration incorporates existing technology for the blood test licensed to BioMosaics, plus new material from SRI needed to improve the test, to be used for assay development at Amorfix. Pending successful development, the product will be commercialized by BioMosaics through its existing distribution network.

The liver cancer blood test is based on antibodies to the biomarker Glypican-3 (GPC3), discovered by Dr. Jorge Filmus at Sunnybrook. The collaboration utilizes BioMosaics' expertise in the cancer biomarker area and the assay development capability at Amorfix. "Our expertise in developing highly sensitive blood assays is part of our core capabilities and we welcome the opportunity to apply our knowledge to achieve a blood test for the early detection of primary liver cancer," said Dr. George Adams, CEO of Amorfix. Antibodies to GPC3 are sold worldwide by BioMosaics for use in pathology laboratories to confirm HCC, and GPC3 is widely accepted as an immunohistochemical biomarker of early HCC. "A robust and sensitive immunoassay for detection of GPC3 circulating in the bloodstream will facilitate monitoring and early detection of liver cancer in high-risk groups such as people with chronic hepatitis," said Dr. Mark Allegretta, President of BioMosaics.

Under this commercial collaboration, BioMosaics will have the opportunity to market the new test directly, as well as through its existing distributors, and Amorfix will receive royalties on commercial product sales, as well as an option to manufacture the assay kits and reagents for global distribution.

About HCC

HCC is the fifth most common cancer in the world, with approximately 600,000 new cases every year. It is the third most common cause of cancer-related death. Early detection could significantly improve treatment outcomes. The main risk factors are chronic Hepatitis B and Hepatitis C virus infection. About 500 million people in the world have chronic hepatitis. Japan has over 5 million people with chronic Hepatitis B or C, and is the country with the most comprehensive approach to testing for HCC. Patients considered at risk for HCC have blood tests as often as every 3 months and imaging procedures up to twice a year. HCC is the most

frequent cancer in China, and causes over 100,000 deaths a year, affecting men mainly 30 to 59 years old. The incidence in North America has doubled in the last 15 years and is increasing. Approximately \$1 billion is currently being spent annually worldwide to screen the disease using surrogate serological markers and imaging such as ultrasound.

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded diseases including neurodegenerative diseases and cancer. It has specific programs in vCJD, ALS and Alzheimer's Disease. Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample containing normal protein. Aggregated misfolded proteins are a common element of many brain wasting diseases and cancer. Amorfix has shown antibodies and vaccines to misfolded proteins are therapeutic in preclinical animal models. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

About BioMosaics

BioMosaics is a privately-held cancer biomarker development company located in Burlington Vermont. The Company is engaged in the development and commercialization of innovative products for the early diagnosis, prediction, monitoring and treatment of cancer. For more information about BioMosaics, visit www.biomosaics.com.

About Ontario Institute of Cancer Research

OICR is a not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation. To find out more about OICR and the "Intellectual Property Development and Commercialization Program", visit www.oicr.on.ca/Commercialization/programs2.htm

About Sunnybrook Health Sciences Centre

Sunnybrook Health Sciences Centre is inventing the future of health care. It is an internationally recognized leader in research and education that is fully affiliated with the University of Toronto, and one of Canada's premier academic health sciences centres. To find out more about Sunnybrook, visit www.sunnybrook.ca

This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

Dr. George Adams
President & Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6959
Fax: (416) 847-6899
george.adams@amorfix.com

James Parsons
Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6929
Fax: (416) 847-6899
james.parsons@amorfix.com

Mark Allegretta PhD
President & Chief Scientific Officer
BioMosaics Inc.
Tel: (802) 656-5442
m.allegretta@biomosaics.com